Targeted therapy may delay end-of-life transition, study finds

12/6/2012 | MedWire News (U.K.)

Targeted therapies such as bevacizumab, erlotinib, sorafenib and rituximab increasingly are used in advanced cancer patients at the end of life, according to research from the University of Texas MD Anderson Cancer Center. The study team wrote in the Journal of Pain and Symptom Management these treatments are used about as often as chemotherapy and could delay a transition in care, "diverting patients' precious time and energy to the pursuit of cancer treatments rather than planning ahead."

View Full Article in:

MedWire News (U.K.)